source
- Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appealTakeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…
- Biopharma must pair innovation with operational readiness to scale therapiesThe article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable pro…